Icagen, Inc. (NASDAQ: ICGN) today announced that several of its senior scientists will present at three upcoming scientific forums as follows:

  • Neil Castle, Ph.D., Director of Biology, will give a presentation entitled ?Use of High Throughput Electrophysiology in Sodium Channel Drug Discovery? at the Joint Society for Biomolecular Sciences and European Laboratory Robotics Interest Group meeting, Drug Discovery: The Application of High-Throughput Technologies to Target and Lead Identification, on Tuesday, October 2, 2007 in Nottingham, England.
  • Mark Chapman, Ph.D., Sr. Research Investigator, will give a presentation entitled ?Identification of Subtype Selective Nav 1.8 Inhibitors? at the IBC Lifesciences conference, Assays & Cellular Targets, on Friday, October 19, 2007 in San Diego, California.
  • Doug Krafte, Ph.D., Vice President Biology, will deliver a presentation entitled ?The Role of Nav1.8 in Chronic Pain States? at the Cambridge Healthtech Institute's Discovery on Target 2007 conference, Ion Channels: An Emerging Target for Therapeutic Development, on Thursday, October 18, 2007 in Boston, Massachusetts.

About Icagen

Icagen, Inc. is a biopharmaceutical company based in Research Triangle Park, North Carolina, focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. Utilizing its proprietary know-how and integrated scientific and drug development capabilities, Icagen has identified multiple drug candidates that modulate ion channels. The Company is conducting research and development activities, in some cases in collaboration with leading pharmaceutical companies, in a number of disease areas, including epilepsy, pain, inflammation, sickle cell disease and dementia, including Alzheimer's disease.

Forward Looking Statements

This press release contains forward-looking statements that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words ?believes,? ?anticipates,? ?plans,? ?expects,? ?intends,? and similar expressions are intended to identify forward-looking statements. Important factors that could cause actual results to differ materially from the expectations described in these forward-looking statements are set forth under the caption ?Risk Factors? in the Company's most recent Quarterly Report on Form 10-Q, filed with the SEC on August 7, 2007. These risk factors include risks as to the Company's history of net losses and how long the Company will be able to operate on its existing capital resources; the Company's ability to raise additional funding; the Company's ability to maintain compliance with NASDAQ's continued listing requirements; whether the Company's products will advance in the clinical trials process; the timing of such clinical trials; whether the results obtained in preliminary studies will be indicative of results obtained in clinical trials; whether the clinical trial results will warrant continued product development; whether and when, if at all, the Company's products, including senicapoc, will receive approval from the U.S. Food and Drug Administration or equivalent regulatory agencies, and for which indications, and if such products receive approval, whether they will be successfully marketed; and the Company's dependence on third parties, including manufacturers, suppliers and collaborators. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Icagen, Inc.
Richard D. Katz, M.D., 919-941-5206
SVP, Finance and Corporate Development;
Chief Financial Officer
rkatz@icagen.com
or
Feinstein Kean Healthcare
Francesca T. Devellis, 617-577-8110
Senior Vice President
Francesca.devellis@fkhealth.com